Humana (NYSE:HUM) is scheduled to post its quarterly earnings results before the market opens on Wednesday, May 1st. Analysts expect Humana to post earnings of $4.29 per share for the quarter. Humana has set its FY 2019 guidance at $17.00-17.50 EPS and its FY19 guidance at $17.00-17.50 EPS.Individual that are interested in registering for the company’s earnings conference call can do so using this link.

Humana (NYSE:HUM) last issued its quarterly earnings data on Wednesday, February 6th. The insurance provider reported $2.65 earnings per share for the quarter, beating the Zacks’ consensus estimate of $2.53 by $0.12. Humana had a return on equity of 19.64% and a net margin of 2.96%. The business had revenue of $14.17 billion during the quarter, compared to analysts’ expectations of $14.04 billion. During the same period in the previous year, the firm posted $2.06 earnings per share. The company’s revenue was up 7.4% on a year-over-year basis. On average, analysts expect Humana to post $18 EPS for the current fiscal year and $20 EPS for the next fiscal year.

Shares of NYSE HUM opened at $248.45 on Wednesday. Humana has a twelve month low of $225.65 and a twelve month high of $355.88. The company has a quick ratio of 1.68, a current ratio of 1.68 and a debt-to-equity ratio of 0.43. The firm has a market capitalization of $32.65 billion, a PE ratio of 17.08, a PEG ratio of 0.99 and a beta of 0.93.

The company also recently disclosed a quarterly dividend, which will be paid on Friday, July 26th. Stockholders of record on Friday, June 28th will be paid a $0.55 dividend. The ex-dividend date of this dividend is Thursday, June 27th. This represents a $2.20 dividend on an annualized basis and a dividend yield of 0.89%. Humana’s payout ratio is presently 15.12%.

A number of equities research analysts have recently weighed in on the company. UBS Group assumed coverage on Humana in a research note on Tuesday. They issued a “neutral” rating and a $266.00 price objective for the company. Stephens assumed coverage on Humana in a research note on Monday, January 14th. They issued an “overweight” rating and a $336.00 price objective for the company. ValuEngine cut Humana from a “hold” rating to a “sell” rating in a research note on Thursday, April 11th. Barclays dropped their price objective on Humana from $351.00 to $327.00 and set an “overweight” rating for the company in a research note on Wednesday, April 17th. Finally, Zacks Investment Research cut Humana from a “buy” rating to a “hold” rating in a research note on Friday, February 8th. Two analysts have rated the stock with a sell rating, four have assigned a hold rating and fourteen have assigned a buy rating to the company. Humana has an average rating of “Buy” and an average price target of $349.11.

In related news, insider Christopher H. Hunter sold 15,586 shares of Humana stock in a transaction on Monday, February 25th. The stock was sold at an average price of $305.24, for a total value of $4,757,470.64. Following the completion of the transaction, the insider now directly owns 28,100 shares in the company, valued at $8,577,244. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Roy A. Beveridge sold 8,278 shares of Humana stock in a transaction on Tuesday, February 19th. The shares were sold at an average price of $307.16, for a total value of $2,542,670.48. Following the completion of the transaction, the insider now owns 12,409 shares of the company’s stock, valued at $3,811,548.44. The disclosure for this sale can be found here. Company insiders own 0.54% of the company’s stock.

TRADEMARK VIOLATION WARNING: This piece was first published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this piece on another website, it was stolen and reposted in violation of US and international trademark and copyright legislation. The legal version of this piece can be accessed at https://www.thecerbatgem.com/2019/04/24/humana-hum-set-to-announce-quarterly-earnings-on-wednesday.html.

Humana Company Profile

Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. The company offers medical and supplemental benefit plans to individuals. It also has contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.

Read More: How Buying a Call Option Works

Earnings History for Humana (NYSE:HUM)

Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.